

Sung-Soo Yoon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8422027/publications.pdf>

Version: 2024-02-01

294
papers

7,732
citations

212478

28
h-index

71088

80
g-index

300
all docs

300
docs citations

300
times ranked

8983
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy and safety of blinatumomab: Post hoc pooled analysis in Asian adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, 311-318.	0.7	6
2	Influence of creatinine levels on survival in patients with veno-occlusive disease treated with defibrotide. <i>Korean Journal of Internal Medicine</i> , 2022, 37, 179-189.	0.7	2
3	Cyclophosphamide addition to pomalidomide/dexamethasone is not necessarily associated with universal benefits in RRMM. <i>PLoS ONE</i> , 2022, 17, e0260113.	1.1	2
4	Successful treatment of angioinvasive aspergillosis causing diaphragmatic rupture with bowel perforation and cerebral aspergillosis in a patient with FLT3-mutated acute myeloid leukemia. <i>Medicine (United States)</i> , 2022, 101, e28700.	0.4	1
5	Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. <i>Blood</i> , 2022, 139, 3366-3375.	0.6	55
6	Eltrombopag for Post-Transplant Poor Graft Function in East Asian Patients. <i>Journal of Korean Medical Science</i> , 2022, 37, e48.	1.1	3
7	Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 481-491.	0.8	160
8	IDH1/2 mutations in acute myeloid leukemia. <i>Blood Research</i> , 2022, 57, 13-19.	0.5	6
9	Idasanutlin Plus Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia: Results of the MIRROS Trial. <i>Blood Advances</i> , 2022, , .	2.5	13
10	Characteristics of Sweet syndrome in patients with or without malignancy. <i>Annals of Hematology</i> , 2022, 101, 1499-1508.	0.8	6
11	Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805). <i>International Journal of Hematology</i> , 2022, , 1.	0.7	0
12	Iptacopan monotherapy in patients with paroxysmal nocturnal hemoglobinuria: a 2-cohort open-label proof-of-concept study. <i>Blood Advances</i> , 2022, 6, 4450-4460.	2.5	21
13	CELESTIMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab plus lenalidomide versus rituximab plus lenalidomide in patients with relapsed or refractory follicular lymphoma who have received ≥ 1 line of systemic therapy. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS7588-TPS7588.	0.8	6
14	Murine double minute 2 inhibition alone or with cytarabine in acute myeloid leukemia: Results from an idasanutlin phase 1/1b study. <i>Leukemia Research</i> , 2021, 100, 106489.	0.4	29
15	Busulfan, etoposide, cytarabine, and melphalan as a high-dose regimen for autologous stem cell transplantation in peripheral T-cell lymphomas. <i>Annals of Hematology</i> , 2021, 100, 189-196.	0.8	2
16	Efficacy and safety of weekly carfilzomib (70 mg/m ²), dexamethasone, and daratumumab (KdD70) is comparable to twice-weekly KdD56 while being a more convenient dosing option: a cross-study comparison of the CANDOR and EQUULEUS studies. <i>Leukemia and Lymphoma</i> , 2021, 62, 358-367.	0.6	13
17	Clinical impact of frailty on treatment outcomes of elderly patients with relapsed and/or refractory multiple myeloma treated with lenalidomide plus dexamethasone. <i>International Journal of Hematology</i> , 2021, 113, 81-91.	0.7	3
18	Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis. <i>BMC Nephrology</i> , 2021, 22, 5.	0.8	14

#	ARTICLE	IF	CITATIONS
19	Carfilzomib in addition to lenalidomide and dexamethasone in Asian patients with RRMM outside of a clinical trial. <i>Annals of Hematology</i> , 2021, 100, 2051-2059.	0.8	6
20	A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Intermediated-risk Acute Myeloid Leukemia Patients. <i>In Vivo</i> , 2021, 35, 617-622.	0.6	1
21	Recent Clinical Update of Acute Myeloid Leukemia: Focus on Epigenetic Therapies. <i>Journal of Korean Medical Science</i> , 2021, 36, e85.	1.1	6
22	Gaucher disease type 1: Unexpected diagnosis in a 75-year old patient presenting with splenomegaly. <i>Current Problems in Cancer</i> , 2021, 45, 100708.	1.0	0
23	Identification of an Optimal Population for Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Mature T and NK Cell Neoplasms. <i>In Vivo</i> , 2021, 35, 2379-2390.	0.6	0
24	Should patients receive consolidation chemotherapy before reduced intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission?. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110011.	1.1	1
25	Prognostic value of integrated cytogenetic, somatic variation, and copy number variation analyses in Korean patients with newly diagnosed multiple myeloma. <i>PLoS ONE</i> , 2021, 16, e0246322.	1.1	5
26	Leukemic stem cell phenotype is associated with mutational profile in acute myeloid leukemia. <i>Korean Journal of Internal Medicine</i> , 2021, 36, 401-412.	0.7	5
27	Noncanonical immune response to the inhibition of DNA methylation by Stau1 via stabilization of endogenous retrovirus RNAs. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	20
28	Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma. <i>Blood</i> , 2021, 137, 3616-3628.	0.6	48
29	Long-Term Efficacy and Safety of the Long-Acting Complement C5 Inhibitor Ravulizumab for the Treatment of Atypical Hemolytic Uremic Syndrome in Adults. <i>Kidney International Reports</i> , 2021, 6, 1603-1613.	0.4	29
30	MOMENTUM: momelotinib vs danazol in patients with myelofibrosis previously treated with JAKi who are symptomatic and anemic. <i>Future Oncology</i> , 2021, 17, 1449-1458.	1.1	31
31	Follow-up of patients with FLT3-mutated R/R AML in the phase 3 ADMIRAL trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 7013-7013.	0.8	3
32	Clinical characteristics and prognostic factors of acquired haemophilia A in Korea. <i>Haemophilia</i> , 2021, 27, e609-e616.	1.0	2
33	Pan-RAF inhibitor LY3009120 is highly synergistic with low-dose cytarabine, but not azacitidine, in acute myeloid leukemia with RAS mutations. <i>Oncology Letters</i> , 2021, 22, 745.	0.8	5
34	Limited benefits of thalidomide and dexamethasone maintenance after autologous stem cell transplantation in newly diagnosed multiple myeloma patients: a prospective phase II multi-center study in Korea. <i>Current Problems in Cancer</i> , 2021, 46, 100786.	1.0	0
35	Immunogenomic pan-cancer landscape reveals immune escape mechanisms and immunoediting histories. <i>Scientific Reports</i> , 2021, 11, 15713.	1.6	10
36	Multicenter, phase II study of response-adapted lenalidomide-based therapy for transplant-ineligible patients with newly diagnosed multiple myeloma without high-risk features. <i>Current Problems in Cancer</i> , 2021, 46, 100788.	1.0	1

#	ARTICLE	IF	CITATIONS
37	Metabolic Profiling during Acute Myeloid Leukemia Progression Using Paired Clinical Bone Marrow Serum Samples. <i>Metabolites</i> , 2021, 11, 586.	1.3	4
38	Romiplostim plus danazol as salvage treatment for eltrombopag refractory immune thrombocytopenia: a retrospective pilot study. <i>Blood Research</i> , 2021, 56, 202-204.	0.5	1
39	Incidence, characteristics and risk factors of thromboembolic events in East Asian patients with BCR-ABL1 negative myeloproliferative neoplasms. <i>Scientific Reports</i> , 2021, 11, 17819.	1.6	6
40	Busulfan plus melphalan versus melphalan alone conditioning regimen after bortezomib based triplet induction chemotherapy for patients with newly diagnosed multiple myeloma. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110129.	1.1	4
41	Daratumumab monotherapy for relapsed/refractory multiple myeloma, focussed on clinical trial unfit patients and subsequent therapy. <i>British Journal of Haematology</i> , 2021, 193, 101-112.	1.2	12
42	Ultradeep Sequencing Analysis of Paroxysmal Nocturnal Hemoglobinuria Clones Detected by Flow Cytometry: <i>PIG</i> Mutation in Small PNH Clones. <i>American Journal of Clinical Pathology</i> , 2021, 156, 72-85.	0.4	2
43	Significance of analyzing circulating plasma cells in multiple myeloma: differences from measuring minimal residual diseases in bone marrow. <i>Leukemia and Lymphoma</i> , 2021, , 1-4.	0.6	1
44	HDAC Inhibition Effectively Induce Apoptosis in Diffuse Large B Cell Lymphoma with High Bfl-1. <i>Blood</i> , 2021, 138, 4320-4320.	0.6	1
45	Late vs Early Response and Depth of Response Are Associated with Improved Outcomes in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Treated with Ixazomib-Lenalidomide-Dexamethasone (IRd) or Placebo-Lenalidomide-Dexamethasone (pbo-Rd) in the Phase 3 TOURMALINE-MM2 Trial. <i>Blood</i> , 2021, 138, 2733-2733.	0.6	1
46	A Phase 1a/1b First in Human Study of PHI-101, a Potent Small Molecule Inhibitor of FLT3 in Relapsed and Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 3425-3425.	0.6	0
47	Subcutaneous (SC) Administration of Mosunetuzumab with Cycle 1 Step-up Dosing Is Tolerable and Active in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphomas (R/R B-NHL): Initial Results from a Phase I/II Study. <i>Blood</i> , 2021, 138, 3573-3573.	0.6	7
48	A Pilot Study of MG4101, Allogeneic Natural Killer Cell, in Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 3835-3835.	0.6	0
49	Association between preconditioning absolute lymphocyte count and transplant outcomes in patients undergoing matched unrelated donor allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning and anti-thymocyte globulin. <i>Therapeutic Advances in Hematology</i> , 2021, 12, 204062072110637.	1.1	7
50	Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studies. <i>Haematologica</i> , 2020, 105, 468-477.	1.7	41
51	Truncation of MYH8 tail in AML: a novel prognostic marker with increase cell migration and epithelial-mesenchymal transition utilizing RAF/MAPK pathway. <i>Carcinogenesis</i> , 2020, 41, 817-827.	1.3	10
52	The Role of Anthracyclines in Acute Myeloid Leukemia Consolidation. <i>Anticancer Research</i> , 2020, 40, 357-366.	0.5	2
53	Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164). <i>TJ ETQq1 1 0.784314 pgBT /Over</i>		
54	The effectiveness and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma in real-world clinical practice: a study of the Korean Multiple Myeloma Working Party (KMMWP-151 study). <i>Annals of Hematology</i> , 2020, 99, 309-319.	0.8	5

#	ARTICLE	IF	CITATIONS
55	NFATc1+CD31+CD45 ^{hi} circulating multipotent stem cells derived from human endocardium and their therapeutic potential. <i>Biomaterials</i> , 2020, 232, 119674.	5.7	4
56	SO054ONE-YEAR EFFICACY AND SAFETY OF THE LONG ACTING C5 INHIBITOR RAVULIZUMAB FOR THE TREATMENT OF ATYPICAL HAEMOLYTIC URAEMIC SYNDROME (AHUS) IN ADULTS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	2
57	Outcomes of decitabine treatment for newly diagnosed acute myeloid leukemia in older adults. <i>PLoS ONE</i> , 2020, 15, e0235503.	1.1	3
58	MED-TMA: A clinical decision support tool for differential diagnosis of TMA with enhanced accuracy using an ensemble method. <i>Thrombosis Research</i> , 2020, 193, 154-159.	0.8	3
59	Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2020, 383, 617-629.	13.9	1,407
60	Allogeneic Stem Cell Transplantation in Relapsed/Refractory Multiple Myeloma Treatment: Is It Still Relevant?. <i>Journal of Clinical Medicine</i> , 2020, 9, 2354.	1.0	1
61	Optimizing Preparative Regimen for Umbilical Cord Blood Transplantation in Adult Acute Leukemia Patients: Acute Lymphoblastic Leukemia Requires Myeloablative Conditioning but Not Acute Myeloid Leukemia. <i>Journal of Clinical Medicine</i> , 2020, 9, 2310.	1.0	1
62	Single-cell analysis of AIMP2 splice variants informs on drug sensitivity and prognosis in hematologic cancer. <i>Communications Biology</i> , 2020, 3, 630.	2.0	7
63	MO020EFFICACY AND SAFETY OF THE LONG-ACTING C5 INHIBITOR RAVULIZUMAB IN PATIENTS WITH POSTPARTUM ATYPICAL HAEMOLYTIC URAEMIC SYNDROME. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.4	5
64	Proper Read Filtering Method to Adequately Analyze Whole-Transcriptome Sequencing and RNA Based Immune Repertoire Sequencing Data for Tumor Milieu Research. <i>Cancers</i> , 2020, 12, 3693.	1.7	1
65	Characterization and Prognosis of Secondary Acute Myeloid Leukemia in an Asian Population: AML With Antecedent Hematological Disease Confers Worst Outcomes, Irrespective of Cytogenetic Risk. <i>Anticancer Research</i> , 2020, 40, 2917-2924.	0.5	7
66	Induction of leukemic stem cell differentiation by aryl hydrocarbon receptor agonist and synergy with gilteritinib in FLT3-ITD ⁺ acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 1932-1942.	0.6	4
67	Phase 1 study of CWP232291 in patients with relapsed or refractory acute myeloid leukemia and myelodysplastic syndrome. <i>Blood Advances</i> , 2020, 4, 2032-2043.	2.5	38
68	Autologous stem cell transplantation in elderly patients with multiple myeloma in Korea: the KMM1807 study. <i>International Journal of Hematology</i> , 2020, 112, 84-95.	0.7	5
69	Denosumab Versus Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Randomized Controlled Phase 3 Study's Asian Subgroup Analysis. <i>Advances in Therapy</i> , 2020, 37, 3404-3416.	1.3	7
70	Incorporating hematopoietic stem-cell transplantation after second-line carfilzomib-lenalidomide-dexamethasone (KRd). <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072092104.	1.1	2
71	Synergistic Effect of Alectinib and Everolimus on ALK-positive Anaplastic Large Cell Lymphoma Growth Inhibition. <i>Anticancer Research</i> , 2020, 40, 1395-1403.	0.5	6
72	Decreased vitamin C uptake mediated by SLC2A3 promotes leukaemia progression and impedes TET2 restoration. <i>British Journal of Cancer</i> , 2020, 122, 1445-1452.	2.9	27

#	ARTICLE	IF	CITATIONS
73	MIRROS: a randomized, placebo-controlled, Phase III trial of cytarabine ± idasanutlin in relapsed or refractory acute myeloid leukemia. <i>Future Oncology</i> , 2020, 16, 807-815.	1.1	53
74	The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. <i>Kidney International</i> , 2020, 97, 1287-1296.	2.6	123
75	Intravenous busulfan and melphalan versus high-dose melphalan as a conditioning regimen for early autologous stem cell transplantation in patients with multiple myeloma: a propensity score-matched analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 2714-2721.	0.6	5
76	Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma. <i>Blood</i> , 2020, 136, 2548-2556.	0.6	17
77	Preconditioning Absolute Lymphocyte Count and Transplantation Outcomes in Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation Recipients with Reduced-Intensity Conditioning and Antithymocyte Globulin Treatment. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1855-1860.	2.0	13
78	Distinct genetic profile with recurrent population-specific missense variants in Korean adult atypical hemolytic uremic syndrome. <i>Thrombosis Research</i> , 2020, 194, 45-53.	0.8	4
79	Pittsburgh B Compound Positron Emission Tomography in Patients With AL Cardiac Amyloidosis. <i>Journal of the American College of Cardiology</i> , 2020, 75, 380-390.	1.2	35
80	The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria. <i>Blood</i> , 2020, 135, 912-920.	0.6	73
81	Association of HSV-1 and Reduced Oral Bacteriota Diversity with Chemotherapy-Induced Oral Mucositis in Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation. <i>Journal of Clinical Medicine</i> , 2020, 9, 1090.	1.0	18
82	Busulfan, etoposide, cytarabine, and melphalan (BuEAM) as a conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma (NHL). <i>Bone Marrow Transplantation</i> , 2020, 55, 1466-1468.	1.3	2
83	Similar transplant outcomes between haploidentical and unrelated donors after reduced-intensity conditioning with busulfan, fludarabine, and anti-thymocyte globulin in patients with acute leukemia or myelodysplastic syndrome. <i>Blood Research</i> , 2020, 55, 27-34.	0.5	2
84	Strong association between herpes simplex virus-1 and chemotherapy-induced oral mucositis in patients with hematologic malignancies. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 1188-1198.	0.7	15
85	An Optimized Crovalimab Dose and Regimen Reduced the Formation of Drug-Target-Drug Complexes in Patients with Paroxysmal Nocturnal Hemoglobinuria from the Phase I/II COMPOSER Trial. <i>Blood</i> , 2020, 136, 2-3.	0.6	2
86	Clinical Course of High-Risk Multiple Myeloma Patients in Korea: A Multicenter Retrospective Study. <i>Blood</i> , 2020, 136, 14-14.	0.6	0
87	Momelotinib's Spleen, Symptom and Anemia Efficacy Is Maintained in Intermediate/High Risk Myelofibrosis Patients with Thrombocytopenia. <i>Blood</i> , 2020, 136, 43-44.	0.6	6
88	Safety Analysis of Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients (pts) with Steroid-Refractory (SR) Acute Graft-Vs-Host Disease (aGVHD) in the Randomized Phase 3 REACH2 Study. <i>Blood</i> , 2020, 136, 40-42.	0.6	0
89	COMPOSER Part 4: An Optimized Dosing Strategy for Crovalimab in the Treatment of Complement Inhibitor-Naïve or -Experienced Patients with Paroxysmal Nocturnal Hemoglobinuria. <i>Blood</i> , 2020, 136, 6-7.	0.6	1
90	Phase 2 Study of Daratumumab in Combination with Thalidomide and Dexamethasone in Asian Patients with Relapsed/Refractory Myeloma (RRMM) - Interim Analysis of a Trial By the Asian Myeloma Network (AMN). <i>Blood</i> , 2020, 136, 21-21.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Outcomes of decitabine treatment for newly diagnosed acute myeloid leukemia in older adults. <i>Leukemia Research</i> , 2020, 15, e0235503.		0
92	Outcomes of decitabine treatment for newly diagnosed acute myeloid leukemia in older adults. <i>Leukemia Research</i> , 2020, 15, e0235503.		0
93	Outcomes of decitabine treatment for newly diagnosed acute myeloid leukemia in older adults. <i>Leukemia Research</i> , 2020, 15, e0235503.		0
94	Outcomes of decitabine treatment for newly diagnosed acute myeloid leukemia in older adults. <i>Leukemia Research</i> , 2020, 15, e0235503.		0
95	Outcomes of decitabine treatment for newly diagnosed acute myeloid leukemia in older adults. <i>Leukemia Research</i> , 2020, 15, e0235503.		0
96	Outcomes of decitabine treatment for newly diagnosed acute myeloid leukemia in older adults. <i>Leukemia Research</i> , 2020, 15, e0235503.		0
97	Targeted sequencing aids in identifying clonality in chronic myelomonocytic leukemia. <i>Leukemia Research</i> , 2019, 84, 106190.	0.4	9
98	Characteristics of Waldenström Macroglobulinemia in Korean Patients According to Mutational Status of MYD88 and CXCR4: Analysis Using Ultra-Deep Sequencing. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e496-e505.	0.2	4
99	Comparison of quality of life and health behaviors in survivors of acute leukemia and the general population. <i>Annals of Hematology</i> , 2019, 98, 2357-2366.	0.8	3
100	Oncogenic effects of germline variants in lysosomal storage disease genes. <i>Genetics in Medicine</i> , 2019, 21, 2695-2705.	1.1	7
101	Telomere length and its correlation with gene mutations in chronic lymphocytic leukemia in a Korean population. <i>PLoS ONE</i> , 2019, 14, e0220177.	1.1	4
102	Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001) a trial by the Asian Myeloma Network. <i>Blood Cancer Journal</i> , 2019, 9, 83.	2.8	9
103	Daratumumab Monotherapy in Heavily Pretreated Asian Patients With Relapsed and Refractory Multiple Myeloma: A Real-world Experience. <i>Anticancer Research</i> , 2019, 39, 5165-5170.	0.5	14
104	The Temporal Sequence and the Differences in Somatic Mutation Acquisition Determines Clinical Behaviors of JAK2-Positive Myeloproliferative Neoplasms. <i>Anticancer Research</i> , 2019, 39, 6273-6282.	0.5	5
105	Optimizing carfilzomib use in multiple myeloma treatment. <i>Blood Research</i> , 2019, 54, 159-161.	0.5	1
106	Incidence and characteristics of venous thromboembolism in Asian patients with primary central nervous system lymphoma undergoing chemotherapy. <i>Thrombosis Research</i> , 2019, 183, 131-135.	0.8	12
107	Comparison of Different Conditioning Regimens in Allogeneic Hematopoietic Stem-Cell Transplantation Shows Superiority of Total Body Irradiation-Based Regimen for Younger Patients With Acute Leukemia: A Nationwide Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, e605-e615.	0.2	7
108	The upregulation of Pim kinases is essential in coordinating the survival, proliferation, and migration of KIT D816V-mutated neoplastic mast cells. <i>Leukemia Research</i> , 2019, 83, 106166.	0.4	1

#	ARTICLE	IF	CITATIONS
109	Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy. <i>BMC Cancer</i> , 2019, 19, 358.	1.1	18
110	ERK-dependent IL-6 positive feedback loop mediates resistance against a combined treatment using danusertib and BKM120 in Burkitt lymphoma cell lines. <i>Leukemia and Lymphoma</i> , 2019, 60, 2532-2540.	0.6	7
111	Replicative senescence of hematopoietic cells in patients with idiopathic cytopenia of undetermined significance. <i>Leukemia Research</i> , 2019, 79, 22-26.	0.4	1
112	Interpretation of EBV infection in pan-cancer genome considering viral life cycle: LiEB (Life cycle of Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	1.6	10
113	Prognostic value of metabolic tumour volume on baseline 18F-FDG PET/CT in addition to NCCN-IPI in patients with diffuse large B-cell lymphoma: further stratification of the group with a high-risk NCCN-IPI. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1417-1427.	3.3	49
114	Combination of Genetic Aberration With International Staging System Classification for Stratification of Asian Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation. <i>In Vivo</i> , 2019, 33, 611-619.	0.6	5
115	Risk of disease transformation and second primary solid tumors in patients with myeloproliferative neoplasms. <i>Blood Advances</i> , 2019, 3, 3700-3708.	2.5	26
116	Distinctive patterns of peripheral neuropathy across the spectrum of plasma cell disorders. <i>Scientific Reports</i> , 2019, 9, 16769.	1.6	6
117	Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement. <i>Cells</i> , 2019, 8, 1538.	1.8	7
118	Pralatrexate in patients with recurrent or refractory peripheral T-cell lymphomas: a multicenter retrospective analysis. <i>Scientific Reports</i> , 2019, 9, 20302.	1.6	12
119	Differential impact of anti-thymocyte globulin dosing by disease risk index in alternative donor peripheral blood stem cell transplantation in patients with acute leukemia or myelodysplastic syndrome after reduced intensity conditioning. <i>Blood Research</i> , 2019, 54, 290-295.	0.5	0
120	Plasma-based protein biomarkers can predict the risk of acute graft-versus-host disease and non-relapse mortality in patients undergoing allogeneic hematopoietic stem cell transplantation. <i>Blood Cells, Molecules, and Diseases</i> , 2019, 74, 5-12.	0.6	7
121	Discovery of donor genotype associated with long-term survival of patients with hematopoietic stem cell transplantation in refractory acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 1775-1781.	0.6	1
122	ASXL1 is a molecular predictor in idiopathic cytopenia of undetermined significance. <i>Leukemia and Lymphoma</i> , 2019, 60, 756-763.	0.6	6
123	Venous thromboembolism in relapsed or refractory multiple myeloma patients treated with lenalidomide plus dexamethasone. <i>International Journal of Hematology</i> , 2019, 109, 79-90.	0.7	9
124	Mosunetuzumab Induces Complete Remissions in Poor Prognosis Non-Hodgkin Lymphoma Patients, Including Those Who Are Resistant to or Relapsing After Chimeric Antigen Receptor T-Cell (CAR-T) Therapies, and Is Active in Treatment through Multiple Lines. <i>Blood</i> , 2019, 134, 6-6.	0.6	152
125	Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma. <i>Blood</i> , 2019, 134, 1285-1285.	0.6	9
126	Characterizing C5 Inhibition with the SMART-Ig Anti-hC5 Antibody Crovalimab in PNH Patients Using Free Available Paratopes. <i>Blood</i> , 2019, 134, 1227-1227.	0.6	5

#	ARTICLE	IF	CITATIONS
127	Managing cytokine release syndrome (CRS) and neurotoxicity with step-fractionated dosing of mosunetuzumab in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (NHL).. Journal of Clinical Oncology, 2019, 37, 7518-7518.	0.8	20
128	Body Cavity-Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma. Cancer Research and Treatment, 2019, 51, 1302-1312.	1.3	6
129	Leukemic Stem Cell Phenotype Is Associated with Mutational Profile in Acute Myeloid Leukemia. Blood, 2019, 134, 3852-3852.	0.6	0
130	Prognostic Implication of Inflammatory Factor-Based Staging System in Multiple Myeloma in the New Agent Era. Blood, 2019, 134, 4372-4372.	0.6	0
131	The Predictors and Prevention of the Central Nervous System Relapse in Patients with Extranodal NK/T Cell Lymphoma, Nasal Type. Blood, 2019, 134, 2847-2847.	0.6	0
132	Exposure-Response Relationship of the SMART-Ig Anti-hC5 Antibody Crovalimab (SKY59): Results from the Umbrella Phase 1/2 Composer Trial in Healthy Volunteers and PNH Patients. Blood, 2019, 134, 3745-3745.	0.6	4
133	Serum Free Light Chain Difference and β_2 Microglobulin Levels Are Risk Factors for Thromboembolic Events in Patients With AL Amyloidosis. Clinical Lymphoma, Myeloma and Leukemia, 2018, 18, 408-414.	0.2	7
134	Which donor is better when a matched donor is not available domestically? Comparison of outcomes of allogeneic stem cell transplantation with haploidentical and international donors in a homogenous ethnic population. Leukemia Research, 2018, 69, 31-38.	0.4	5
135	Satisfaction with sexual activity and sexual dysfunction in hematopoietic stem cell transplantation survivors and their partners: a couple study. Bone Marrow Transplantation, 2018, 53, 967-976.	1.3	14
136	Distinct predictive impact of $\text{t}(11q23)$ FISH abnormality in proteasome inhibitors and immunomodulatory agents response: redefining high-risk multiple myeloma in Asian patients. Cancer Medicine, 2018, 7, 831-841.	1.3	12
137	Phase 2 Study of an Intravenous Busulfan and Melphalan Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma (KMM150). Biology of Blood and Marrow Transplantation, 2018, 24, 923-929.	2.0	10
138	Daratumumab, lenalidomide, and dexamethasone in East Asian patients with relapsed or refractory multiple myeloma: subgroup analyses of the phase 3 POLLUX study. Blood Cancer Journal, 2018, 8, 41.	2.8	32
139	Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma. New England Journal of Medicine, 2018, 378, 518-528.	13.9	747
140	Better treatment outcomes in patients with actively treated therapy-related myeloid neoplasms harboring a normal karyotype. PLoS ONE, 2018, 13, e0209800.	1.1	2
141	The Derived Neutrophil-to-Lymphocyte Ratio Is an Independent Prognostic Factor in Transplantation Ineligible Patients with Multiple Myeloma. Acta Haematologica, 2018, 140, 146-156.	0.7	13
142	Multiple myeloma in Korea: risk stratification and initial treatment. Blood Research, 2018, 53, 183.	0.5	1
143	RTK-RAS pathway mutation is enriched in myeloid sarcoma. Blood Cancer Journal, 2018, 8, 43.	2.8	27
144	Shifting of erythroleukemia to myelodysplastic syndrome according to the revised WHO classification: Biologic and cytogenetic features of shifted erythroleukemia. Leukemia Research, 2018, 70, 13-19.	0.4	3

#	ARTICLE	IF	CITATIONS
145	Allogeneic Stem Cell Transplantation for Patients with Natural Killer/T Cell Lymphoid Malignancy: A Multicenter Analysis Comparing Upfront and Salvage Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2471-2478.	2.0	24
146	Busulfan plus melphalan versus high-dose melphalan as conditioning regimens in autologous stem cell transplantation for newly diagnosed multiple myeloma. <i>Blood Research</i> , 2018, 53, 105.	0.5	9
147	The SMART Anti-hc5 Antibody (SKY59/RO7112689) Shows Good Safety and Efficacy in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). <i>Blood</i> , 2018, 132, 535-535.	0.6	8
148	Genomic and Immune Profiles of Multiple Myeloma Revealed By Whole Genome and Transcriptome Sequencing. <i>Blood</i> , 2018, 132, 4493-4493.	0.6	2
149	Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study. <i>Blood</i> , 2018, 132, 399-399.	0.6	48
150	Asian Subgroup Analysis - Denosumab Vs Zoledronic Acid in Bone Disease Treatment of Newly Diagnosed Multiple Myeloma: An International, Double-Blind, Double-Dummy, Randomized Controlled Phase 3 Study. <i>Blood</i> , 2018, 132, 3251-3251.	0.6	0
151	Allogeneic Hematopoietic Cell Transplantation for Severe Idiopathic Aplastic Anemia Older Than 40y. <i>Blood</i> , 2018, 132, 3876-3876.	0.6	0
152	Identification of Novel Functional Variants of SIN3A and SRSF1 among Somatic Variants in Acute Myeloid Leukemia Patients. <i>Molecules and Cells</i> , 2018, 41, 465-475.	1.0	4
153	Salvage therapy for acute chemorefractory leukemia by allogeneic stem cell transplantation: the Korean experience. <i>Annals of Hematology</i> , 2017, 96, 605-615.	0.8	5
154	BCR-ABL translocation as a favorable prognostic factor in elderly patients with acute lymphoblastic leukemia in the era of potent tyrosine kinase inhibitors. <i>Haematologica</i> , 2017, 102, e187-e190.	1.7	13
155	Continuous treatment with lenalidomide and low-dose dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma in Asia: subanalysis of the FIRST trial. <i>British Journal of Haematology</i> , 2017, 176, 743-749.	1.2	14
156	Identification of somatic mutations using whole-exome sequencing in Korean patients with acute myeloid leukemia. <i>BMC Medical Genetics</i> , 2017, 18, 23.	2.1	5
157	Efficacy and toxicity of the combination chemotherapy of thalidomide, alkylating agent, and steroid for relapsed/refractory myeloma patients: a report from the Korean Multiple Myeloma Working Party (KMMWP) retrospective study. <i>Cancer Medicine</i> , 2017, 6, 100-108.	1.3	5
158	Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials. <i>International Journal of Hematology</i> , 2017, 106, 229-239.	0.7	30
159	Benefits of hypomethylating therapy in IPSS lower-risk myelodysplastic syndrome patients: A retrospective multicenter case series study. <i>Leukemia Research</i> , 2017, 60, 135-144.	0.4	8
160	Epidemiology and Risk Factors for Invasive Fungal Diseases among Allogeneic Hematopoietic Stem Cell Transplant Recipients in Korea: Results of a RISK Study. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1773-1779.	2.0	29
161	Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial. <i>British Journal of Haematology</i> , 2017, 179, 66-74.	1.2	16
162	MCM7 polymorphisms associated with the AML relapse and overall survival. <i>Annals of Hematology</i> , 2017, 96, 93-98.	0.8	14

#	ARTICLE	IF	CITATIONS
163	Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma. <i>Blood Advances</i> , 2017, 1, 2138-2146.	2.5	27
164	The limited role of serum galactomannan assay in screening for invasive pulmonary aspergillosis in allogeneic stem cell transplantation recipients on micafungin prophylaxis: a retrospective study. <i>Blood Research</i> , 2017, 52, 300.	0.5	5
165	Safety and efficacy of daratumumab-based regimens in elderly (≥75 y) patients (Pts) with relapsed or refractory multiple myeloma (RRMM): Subgroup analysis of POLLUX and CASTOR. <i>Journal of Clinical Oncology</i> , 2017, 35, 8033-8033.	0.8	3
166	A phase II/III, multicenter, open-label, 3-arm study of gilteritinib, gilteritinib plus azacitidine, or azacitidine alone in the treatment of newly diagnosed FLT3 mutation-positive acute myeloid leukemia (AML) patients ineligible for intensive induction chemotherapy. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS7068-TPS7068.	0.8	6
167	Novel phase 1a/1b dose-finding study design of CWP232291 (CWP291) in relapsed or refractory myeloma (MM). <i>Journal of Clinical Oncology</i> , 2017, 35, TPS8058-TPS8058.	0.8	3
168	Topical Recombinant Human Epidermal Growth Factor for Oral Mucositis Induced by Intensive Chemotherapy with Hematopoietic Stem Cell Transplantation: Final Analysis of a Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial. <i>PLoS ONE</i> , 2017, 12, e0168854.	1.1	13
169	A prospective, open-label, multicenter, observational study to evaluate the efficacy and safety of bortezomib-melphalan-prednisone as initial treatment for autologous stem cell transplantation-ineligible patients with multiple myeloma. <i>Oncotarget</i> , 2017, 8, 37605-37618.	0.8	6
170	The role of frontline autologous stem cell transplantation for primary plasma cell leukemia: a retrospective multicenter study (KMM160). <i>Oncotarget</i> , 2017, 8, 79517-79526.	0.8	16
171	Clinicopathological characteristics of extremely young Korean multiple myeloma patients: therapeutic implications. <i>Korean Journal of Internal Medicine</i> , 2017, 32, 722-730.	0.7	7
172	Predictive Factors of Mortality in Population of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH): Results from a Korean PNH Registry. <i>Journal of Korean Medical Science</i> , 2016, 31, 214.	1.1	51
173	A scientific treatment approach for acute mast cell leukemia: using a strategy based on next-generation sequencing data. <i>Blood Research</i> , 2016, 51, 17.	0.5	6
174	Highly Expressed Integrin- α 8 Induces Epithelial to Mesenchymal Transition-Like Features in Multiple Myeloma with Early Relapse. <i>Molecules and Cells</i> , 2016, 39, 898-908.	1.0	31
175	Changes in serum uric acid levels after allogeneic hematologic stem cell transplantation: A retrospective cohort study. <i>Blood Research</i> , 2016, 51, 200.	0.5	5
176	The Impact of Methylenetetrahydrofolate Reductase C677T Polymorphism on Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation with Methotrexate Prophylaxis. <i>PLoS ONE</i> , 2016, 11, e0163998.	1.1	9
177	Prognostic Impact of IPSS-R and Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome. <i>PLoS ONE</i> , 2016, 11, e0166245.	1.1	6
178	Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea. <i>Journal of Korean Medical Science</i> , 2016, 31, 1516.	1.1	21
179	SLC29A1 (ENT1) polymorphisms and outcome of complete remission in acute myeloid leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 533-540.	1.1	16
180	Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. <i>New England Journal of Medicine</i> , 2016, 375, 1319-1331.	13.9	1,210

#	ARTICLE	IF	CITATIONS
181	Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia. <i>Annals of Hematology</i> , 2016, 95, 1777-1786.	0.8	17
182	Genetic Association of <i>PARP15</i> Polymorphisms with Clinical Outcome of Acute Myeloid Leukemia in a Korean Population. <i>Genetic Testing and Molecular Biomarkers</i> , 2016, 20, 696-701.	0.3	15
183	Clinical outcome and efficacy of current anti-leukemic therapy for leptomeningeal involvement in acute myeloid leukemia. <i>International Journal of Hematology</i> , 2016, 104, 574-581.	0.7	5
184	Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial. <i>Lancet Haematology</i> , 2016, 3, e506-e515.	2.2	121
185	MicroRNA-139-5p regulates proliferation of hematopoietic progenitors and is repressed during BCR-ABL-mediated leukemogenesis. <i>Blood</i> , 2016, 128, 2117-2129.	0.6	27
186	Monitoring of the Clonal Fraction by Fluorescence In Situ Hybridization in Myelodysplastic Syndrome: Comparison With International Working Group Treatment Response Criteria. <i>Archives of Pathology and Laboratory Medicine</i> , 2016, 140, 560-569.	1.2	5
187	Burden of cytogenetically abnormal plasma cells in light chain amyloidosis and their prognostic relevance. <i>Leukemia Research</i> , 2016, 44, 45-52.	0.4	7
188	Distinct subgroups of paroxysmal nocturnal hemoglobinuria (PNH) with cytopenia: results from South Korean National PNH Registry. <i>Annals of Hematology</i> , 2016, 95, 125-133.	0.8	14
189	Psychometric analysis of the Korean version of the high-dose chemotherapy specific quality of life questionnaire module from the European Organization for Research and Treatment of Cancer (EORTC) Tj ETQq1 1 0.784314ogBT /O		
190	A Case of Dasatinib-Induced Hemorrhagic Colitis Diagnosed by the Lymphocyte Transformation Test in a Chronic Myeloid Leukemia Patient. <i>Indian Journal of Hematology and Blood Transfusion</i> , 2016, 32, 96-99.	0.3	5
191	Pomalidomide Plus Dexamethasone (Pd) in the Treatment of Asian Patients with Relapsed/Refractory Myeloma (RRMM) Who Are Previously Treated with Bortezomib and Refractory to Lenalidomide - Interim Analysis of a Trial By the Asian Myeloma Network (AMN). <i>Blood</i> , 2016, 128, 2130-2130.	0.6	7
192	Decitabine Is Superior to Cytotoxic Chemotherapy in Elderly Acute Myeloid Leukemia Patients in Terms of Medical Source Utilization and Cost-Effectiveness without Negatively Impacting Survival Outcomes. <i>Blood</i> , 2016, 128, 2381-2381.	0.6	4
193	A rare case of Rosai-Dorfman disease without lymphadenopathy. <i>Korean Journal of Internal Medicine</i> , 2016, 31, 802-804.	0.7	6
194	Real World Treatment Outcomes of Multiple Myeloma in Korea. <i>Blood</i> , 2016, 128, 2367-2367.	0.6	2
195	Differentiating Thrombotic Microangiopathies Based on Laboratory Tests Other Than ADAMTS13 Using Machine Learning Technology. <i>Blood</i> , 2016, 128, 3749-3749.	0.6	0
196	Retrospective Case Series Study of Hypomethylating Therapy in IPSS Lower-Risk Myelodysplastic Syndrome. <i>Blood</i> , 2016, 128, 1992-1992.	0.6	1
197	Prognostic Impact of Chromosomal Translocations in 751 Korean Patients with Primary Myelodysplastic Syndrome. <i>Blood</i> , 2016, 128, 5432-5432.	0.6	0
198	Analysis of Adverse Events of Dasatinib and Nilotinib in Chronic Phase Chronic Myeloid Leukemia Patients Treated Outside Clinical Trials. <i>Blood</i> , 2016, 128, 1902-1902.	0.6	0

#	ARTICLE	IF	CITATIONS
199	Improved Sensitivity in Detection of FMS-like Tyrosine Kinase Internal Tandem Duplication of a Method Using Next-Generation Sequencing Data. <i>Blood</i> , 2016, 128, 2844-2844.	0.6	0
200	The Outcomes of Korean Patients with Primary Plasma Cell Leukemia: Analysis of Korean Multiple Myeloma Working Party (KMM160). <i>Blood</i> , 2016, 128, 4445-4445.	0.6	0
201	Quality-of-Life and Health Behaviors in Survivors of Acute Leukemia Compared with the General Population: A Population-Based Matched Case-Control Study. <i>Blood</i> , 2016, 128, 5981-5981.	0.6	0
202	Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. <i>Blood</i> , 2015, 126, 746-756.	0.6	160
203	Efficacy of antiviral prophylaxis in HBsAg-negative, anti-HBc positive patients undergoing hematopoietic stem cell transplantation. <i>Liver International</i> , 2015, 35, 2530-2536.	1.9	24
204	Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide. <i>Haematologica</i> , 2015, 100, 826-833.	1.7	76
205	Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea. <i>Blood Research</i> , 2015, 50, 7.	0.5	4
206	Revealing Genomic Profile That Underlies Tropism of Myeloma Cells Using Whole Exome Sequencing. <i>International Journal of Genomics</i> , 2015, 2015, 1-7.	0.8	5
207	¹¹ C-Pittsburgh B PET Imaging in Cardiac Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 50-59.	2.3	135
208	Cytidine deaminase polymorphisms and worse treatment response in normal karyotype AML. <i>Journal of Human Genetics</i> , 2015, 60, 749-754.	1.1	16
209	Final Analysis of Overall Survival from the Phase 3 Panorama 1 Trial of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2015, 126, 3026-3026.	0.6	5
210	Continuous Treatment with Lenalidomide and Low-Dose Dexamethasone in Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma in Asia: Subanalysis of the First Trial. <i>Blood</i> , 2015, 126, 4240-4240.	0.6	3
211	Ethnic Difference in Genomic Profiles of Chronic Lymphocytic Leukemia in Korea: Targeted Exome Sequencing and Molecular Cytogenetics. <i>Blood</i> , 2015, 126, 1726-1726.	0.6	1
212	A New Prognostic Model for Multiple Myeloma Patients in the Era of Novel Agents. <i>Blood</i> , 2015, 126, 4185-4185.	0.6	0
213	Analysis of Outcomes Based on Response in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma Treated with Panobinostat or Placebo in Combination with Bortezomib and Dexamethasone in the Panorama 1 Trial: Updated Analysis Based on Prior Treatment. <i>Blood</i> , 2015, 126, 4230-4230.	0.6	0
214	Genetic Profile and Novel Thrombospondin-1 (THBS1) Mutation of Familial AML Syndrome: A Genomic Analysis By Whole Genome Sequencing and Whole Transcriptome Sequencing. <i>Blood</i> , 2015, 126, 2595-2595.	0.6	0
215	Clinical Response to Idasanutlin (RG7388) in Acute Myeloid Leukemia Patients Is Associated with Pre-Treatment MDM2 Protein Expression in Leukemic Blasts and Leukemic Stem Cells. <i>Blood</i> , 2015, 126, 2580-2580.	0.6	0
216	Establishment and characterization of bortezomib-resistant U266 cell line: Constitutive activation of NF- κ B-mediated cell signals and/or alterations of ubiquitylation-related genes reduce bortezomib-induced apoptosis. <i>BMB Reports</i> , 2014, 47, 274-279.	1.1	20

#	ARTICLE	IF	CITATIONS
217	Establishment of Cell Lines from Both Myeloma Bone Marrow and Plasmacytoma: SNU_MM1393_BM and SNU_MM1393_SC from a Single Patient. <i>BioMed Research International</i> , 2014, 2014, 1-8.	0.9	4
218	Allogeneic stem cell transplantation in patients with de novo diffuse large B-cell lymphoma who experienced relapse or progression after autologous stem cell transplantation: a Korea-Japan collaborative study. <i>Annals of Hematology</i> , 2014, 93, 1345-1351.	0.8	11
219	Chromosome 13 deletion and hypodiploidy on conventional cytogenetics are robust prognostic factors in Korean multiple myeloma patients: web-based multicenter registry study. <i>Annals of Hematology</i> , 2014, 93, 1353-1361.	0.8	18
220	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1195-1206.	5.1	695
221	The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma. <i>Blood</i> , 2014, 124, 2190-2195.	0.6	108
222	Mutation in Retinoic X Receptor- β Is a Possible Mechanism of All-Trans Retinoic Acid Resistance in Acute Promyelocytic Leukemia (APL): Identifying Genetic Changes Related to Drug Resistance in APL Using Whole Exome Sequencing. <i>Blood</i> , 2014, 124, 2358-2358.	0.6	3
223	Everolimus in Combination with Crizotinib Synergistically Inhibits the Growth of ALK-Positive Anaplastic Large Cell Lymphoma Cells. <i>Blood</i> , 2014, 124, 4488-4488.	0.6	1
224	Efficacy and Safety Based on Duration of Treatment of Panobinostat Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma in the Phase 3 Panorama 1 Study. <i>Blood</i> , 2014, 124, 4742-4742.	0.6	3
225	Health-related quality of life (HRQOL) in transplant-ineligible patients (pts) with newly diagnosed multiple myeloma (NDMM): Results from the first trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8516-8516.	0.8	2
226	Hepatic sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation in adult patients with idiopathic aplastic anemia. <i>Leukemia Research</i> , 2013, 37, 1241-1247.	0.4	6
227	Combined interaction of multi-locus genetic polymorphisms in cytarabine arabinoside metabolic pathway on clinical outcomes in adult acute myeloid leukaemia (AML) patients. <i>European Journal of Cancer</i> , 2013, 49, 403-410.	1.3	25
228	Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2013, 161, 339-347.	1.2	72
229	Clinical signs and symptoms associated with increased risk for thrombosis in patients with paroxysmal nocturnal hemoglobinuria from a Korean Registry. <i>International Journal of Hematology</i> , 2013, 97, 749-757.	0.7	98
230	Genomic Characterization Of Newly Established Two Distinct Patient-Driven Multiple Myeloma Cell Lines (SNU_MM1393_BM and SNU_MM1393_SC) From a Single Patient. <i>Blood</i> , 2013, 122, 5361-5361.	0.6	0
231	Response Adapted Lenalidomide Based Therapy For Newly Diagnosed (ND) Standard Risk Older Adults With Multiple Myeloma (MM): An International Collaboration. <i>Blood</i> , 2013, 122, 3201-3201.	0.6	0
232	Observational Study Of VMP (Bortezomib, melphalan, prednisolone) Regimen For Newly Diagnosed Korean Myeloma Patients Who Are Not Eligible For Transplantation. <i>Blood</i> , 2013, 122, 5379-5379.	0.6	0
233	Nilotinib Combined With Multi-Agent Chemotherapy For Adult Patients With Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Final Results Of Prospective Multicenter Phase 2 Study. <i>Blood</i> , 2013, 122, 55-55.	0.6	4
234	Mitoxantrone, etoposide, cytarabine, and melphalan (NEAM) followed by autologous stem cell transplantation for patients with chemosensitive aggressive non-Hodgkin lymphoma. <i>American Journal of Hematology</i> , 2012, 87, 479-483.	2.0	16

#	ARTICLE	IF	CITATIONS
235	Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial. <i>Annals of Hematology</i> , 2012, 91, 249-256.	0.8	15
236	Eltrombopag Treatment of Thrombocytopenia in Advanced Myelodysplastic Syndromes and Acute Myeloid Leukemia: Results of the 8-Week Open-Label Part of an Ongoing Study. <i>Blood</i> , 2012, 120, 3822-3822.	0.6	14
237	Phase III study of panobinostat with bortezomib and dexamethasone in patients with relapsed multiple myeloma (PANORAMA 1).. <i>Journal of Clinical Oncology</i> , 2012, 30, e18572-e18572.	0.8	5
238	Clinical Profile of Multiple Myeloma in Asia - an Asian Myeloma Network (AMN) Study. <i>Blood</i> , 2012, 120, 5035-5035.	0.6	0
239	Risk of Thromboembolism in Patients with Paroxysmal Nocturnal Hemoglobinuria Presenting with Both Clinical Symptoms and Elevated Hemolysis. <i>Blood</i> , 2012, 120, 1273-1273.	0.6	0
240	Sequential High-Dose Dexamethasone and Response Adapted PAD (Bortezomib, Adriamycin,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 552 High-Dose Therapy with ASCT for Newly Diagnosed Multiple Myeloma; Open-Labeled, Multicenter Phase 2 Study (KMM-94 Study)-Interim Analysis.. <i>Blood</i> , 2012, 120, 3106-3106.	0.6	7
241	Comparison of Fluorescence in Situ Hybridization (FISH) for EVI1 Rearrangement (3q26) and G-Banding in Patients with Acute Myeloid Leukemia with Inv(3) or t(3;3).. <i>Blood</i> , 2012, 120, 2540-2540.	0.6	0
242	Comparison between Matched Related and Alternative Donors of Allogeneic Hematopoietic Stem Cells Transplanted into Adult Patients with Acquired Aplastic Anemia: Multivariate and Propensity Score-Matched Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 1289-1298.	2.0	16
243	Allogeneic stem cell transplantation in patients with non-Hodgkin lymphoma who experienced relapse or progression after autologous stem cell transplantation. <i>Annals of Hematology</i> , 2011, 90, 1409-1418.	0.8	7
244	Nilotinib Combined with Multi-Agent Chemotherapy for Adult Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Interim Results of Korean Adult ALL Working Party Phase 2 Study. <i>Blood</i> , 2011, 118, 1517-1517.	0.6	6
245	Therapeutic Comparison of Surgical Resection Followed by R-CHOP and R-CHOP Alone for Primary Localized Intestinal Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2011, 118, 1627-1627.	0.6	1
246	Novel AKT Inhibitor GSK2110183 Shows Favorable Safety, Pharmacokinetics, and Clinical Activity in Multiple Myeloma. Preliminary Results From a Phase I First-Time-In-Human Study. <i>Blood</i> , 2011, 118, 1856-1856.	0.6	10
247	Uncontrolled Complement Activation and the Resulting Chronic Hemolysis As Measured by LDH Serum Level At Diagnosis As Predictor of Thrombotic Complications and Mortality in a Large Cohort of Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH).. <i>Blood</i> , 2011, 118, 3166-3166.	0.6	7
248	Update on a Phase III Study of Panobinostat with Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma: PANORAMA 1,. <i>Blood</i> , 2011, 118, 3976-3976.	0.6	12
249	Vantage 095: Vorinostat in Combination with Bortezomib in Salvage Multiple Myeloma Patients: Final Study Results of a Global Phase 2b Trial. <i>Blood</i> , 2011, 118, 480-480.	0.6	21
250	Vantage 088: Vorinostat in Combination with Bortezomib in Patients with Relapsed/Refractory Multiple Myeloma: Results of a Global, Randomized Phase 3 Trial. <i>Blood</i> , 2011, 118, 811-811.	0.6	16
251	Sequential High-Dose Dexamethasone and Response Adapted PAD (Bortezomib, Adriamycin,) Tj ETQqI 1 0.784314 rgBT /Overlock 10 Tf 50 552 by High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma; Open-Labelled, Multicenter Phase 2 Study (KMM-94 Study)-Interim Analysis. <i>Blood</i> , 2011, 118, 2044-2044.	0.6	19
252	Leukopenia in Patients with Iron Deficiency Anemia. <i>Blood</i> , 2011, 118, 5279-5279.	0.6	2

#	ARTICLE	IF	CITATIONS
253	Hematologic Improvement with Iron Chelation using therapy Deferasirox in Patients with Aplastic Anemia: A Subgroup Analysis of KAMS0112 Prospective Study,. Blood, 2011, 118, 3424-3424.	0.6	0
254	Matched-Pair Analysis Comparing Outcomes of Second Autologous Stem Cell Transplantation and Chemotherapy As a Salvage Therapy in Patients with Multiple Myeloma Who Relapsed After Front-Line Autologous Stem Cell Transplantation. Blood, 2011, 118, 1990-1990.	0.6	0
255	Bortezomib Induction Followed by ASCT in Patients with Multiple Myeloma: Achievement of Response After Induction and Achieving CR Post-ASCT Are Both Important Prognostic Markers. Blood, 2011, 118, 1866-1866.	0.6	0
256	Early Response to Bortezomib Combined Chemotherapy Can Be Helpful for Prediction of Progression Free Survival in Patients with Multiple Myeloma Who Were Ineligible for Stem Cell Transplantation. Blood, 2011, 118, 5138-5138.	0.6	0
257	Hepatic Sinusoidal Obstruction Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acquired Aplastic Anemia. Blood, 2011, 118, 3012-3012.	0.6	0
258	Impact of Cytokine Gene Polymorphisms on Risk and Treatment Outcomes of Aplastic Anemia. Blood, 2011, 118, 4369-4369.	0.6	0
259	Fludarabine, Cytarabine, and Attenuated-Dose Idarubicin (m-FLAI) Induction for Elderly Patients with Acute Myeloid Leukemia: Results of a Multicenter Phase II Study,. Blood, 2011, 118, 3626-3626.	0.6	0
260	Impact of Severe Pain on Outcomes in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH). Blood, 2011, 118, 5273-5273.	0.6	0
261	Frequent Clonal Evolution in Multiple Myeloma,. Blood, 2011, 118, 3919-3919.	0.6	0
262	Hematologic Responses in Patients with Aplastic Anemia Treated with Deferasirox: A Post-Hoc Analysis From the EPIC Study. Blood, 2011, 118, 1344-1344.	0.6	0
263	Low incidence of clinically apparent thromboembolism in Korean patients with multiple myeloma treated with thalidomide. Annals of Hematology, 2010, 89, 201-206.	0.8	30
264	Multiple myeloma in Korea: past, present, and future perspectives. Experience of the Korean Multiple Myeloma Working Party. International Journal of Hematology, 2010, 92, 52-57.	0.7	41
265	Prognosis of Secondary Acute Myeloid Leukemia is Affected by the Type of the Preceding Hematologic Disorders and the Presence of Trisomy 8. Japanese Journal of Clinical Oncology, 2010, 40, 1037-1045.	0.6	25
266	Vorinostat Combined with Bortezomib In Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Update on the Vantage Study Program. Blood, 2010, 116, 1952-1952.	0.6	3
267	Non-A type nucleophosmin 1 gene mutation predicts poor clinical outcome in de novo adult acute myeloid leukemia: differential clinical importance of NPM1 mutation according to subtype. International Journal of Hematology, 2009, 90, 1-5.	0.7	25
268	Different clinical importance of FLT3 internal tandem duplications in AML according to FAB classification: possible existence of distinct leukemogenesis involving monocyte differentiation pathway. Annals of Hematology, 2009, 88, 1089-1097.	0.8	12
269	The Prognostic Impact of Fluorescent-in Situ Hybridization (FISH) and Conventional Karyotyping in Korean Multiple Myeloma Patients: A Retrospective Multicenter Study.. Blood, 2009, 114, 4902-4902.	0.6	1
270	Cost Analysis of Iron-Related Complications in a Single Institute. Korean Journal of Internal Medicine, 2009, 24, 33.	0.7	8

#	ARTICLE	IF	CITATIONS
271	Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells. <i>Molecular Oncology</i> , 2008, 2, 317-326.	2.1	69
272	Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (Bortezomib, Thalidomide,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 71. Transplantation and Maintenance Treatment with Bortezomib for Newly Diagnosed Multiple Myeloma: Final Analysis of Phase II Trial.. <i>Blood</i> , 2008, 112, 3330-3330.	0.6	22
273	Gain of 1q as a Potential Adverse Prognostic Marker in Myelodysplastic Syndrome: Comparison with International Prognostic Scoring System Variables. <i>Blood</i> , 2008, 112, 3640-3640.	0.6	2
274	A Multi-Center, Open Label Study Evaluating the Efficacy of Iron Chelation Therapy with Deferasirox in Transfusional Iron Overload Patients with Myelodysplastic Syndromes or Aplastic Anemia Using Quantitative R2 MRI. <i>Blood</i> , 2008, 112, 3649-3649.	0.6	4
275	Bortezomib-Based Induction Therapy Induces Better Responses and Outcomes of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: The Results of Korean Multiple Myeloma Working Party Retrospective Study, KMM84. <i>Blood</i> , 2008, 112, 5184-5184.	0.6	1
276	Abrogation of U266 Multiple Myeloma Cell Proliferation Via Inhibition of NF- κ B Activation by Curcumin. <i>The Korean Journal of Hematology</i> , 2008, 43, 19.	0.7	0
277	The Comparison Between Matched Related Donor and Alternative Donor for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acquired Aplastic Anemia: KSBMT2007-02 Study. <i>Blood</i> , 2008, 112, 2997-2997.	0.6	1
278	Inactivation of JAK/STAT Cell Signaling by SK-7041, a Novel HDAC Inhibitor, Effectively Inhibits Growth of Acute Myeloid Leukemia Cells. <i>Blood</i> , 2008, 112, 4005-4005.	0.6	0
279	Molecular Predictive Markers in Dose Escalation Treatment for Suboptimal Responders to Standard Dose Imatinib in CML. <i>Blood</i> , 2008, 112, 3221-3221.	0.6	0
280	Is Acute Erythroid Leukemia a Transitional Stage from MDS to AML?: A Study by Fluorescence in Situ Hybridization and Cytogenetics. <i>Blood</i> , 2008, 112, 4867-4867.	0.6	0
281	FLT3, CD32, PU.1, ERG, uPAR, and TAP2 Are Strongly Associated with the Progression of Chronic Myeloid Leukemia and Combination of Small Interference RNA of FLT3 and STI571 Synergistically Induced Apoptosis of K562 Cells. <i>Blood</i> , 2008, 112, 4237-4237.	0.6	0
282	Low Incidence of Thromboembolism in Asian Multiple Myeloma Patients Treated with Thalidomide: Do We Really Need Prophylaxis for Thromboembolism in Asian Population?. <i>Blood</i> , 2008, 112, 5146-5146.	0.6	0
283	Hereditary Hemolytic Anemia in Korea: a Retrospective Study from 1997 to 2006. <i>The Korean Journal of Hematology</i> , 2007, 42, 197.	0.7	15
284	Sequential VAD (Vincristine, Adriamycin, Dexamethasone) and VTD (VELCADE®, Thalidomide,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 23. Transplantation and Maintenance Treatment with VELCADE for Newly Diagnosed Multiple Myeloma: Interim Results of Phase II Trial.. <i>Blood</i> , 2007, 110, 952-952.	0.6	4
285	Novel Synthetic Histone Deacetylase Inhibitor, SK-7041, Has Potent Anti-Proliferative Activity in Acute Myeloid Leukemia Cell Lines.. <i>Blood</i> , 2007, 110, 2854-2854.	0.6	0
286	Blockage of IL-6 Mediated JAK2/STAT3 Cell Signaling Pathway by sIL-6R Effectively Inhibited the Growth of Multiple Myeloma Cell.. <i>Blood</i> , 2006, 108, 5083-5083.	0.6	0
287	The Clinical Efficacy of Helicobacter pylori Eradication in Patients with Helicobacter pylori-positive Chronic Thrombocytopenic Purpura. <i>The Korean Journal of Hematology</i> , 2005, 40, 23.	0.7	2
288	Novel Synthetic Histone Deacetylase Inhibitor (SK-7041) Potently Inhibits Proliferation in Acute Myeloid Leukemia Cell Lines.. <i>Blood</i> , 2005, 106, 4407-4407.	0.6	7

#	ARTICLE	IF	CITATIONS
289	Toxicity Profiles in Patients Using Bortezomib for Multiple Myeloma: Korean Multicenter Analysis.. Blood, 2005, 106, 3500-3500.	0.6	0
290	Extramedullary Relapse Confirmed by Fluorescence In Situ Hybridization Study of an Ear Mass in Acute Promyelocytic Leukemia. International Journal of Hematology, 2004, 79, 462-464.	0.7	5
291	Adult patients with t(8;21) acute myeloid leukemia had no superior treatment outcome to those without t(8;21): a single institution's experience. Annals of Hematology, 2004, 83, 218-224.	0.8	13
292	Multicentric Castleman's disease complicated by tumor lysis syndrome. Annals of Hematology, 2004, 83, 722-725.	0.8	16
293	Effect of the Combination of Imatinib Mesylate (Glivec) and Curcumin in Chronicm Myeloid Leukemia Cell Line.. Blood, 2004, 104, 4685-4685.	0.6	1
294	Adrenal cortical carcinoma initially presented with overwhelming disseminated intravascular coagulation. Annals of Hematology, 2003, 82, 596-598.	0.8	4